1,151 Shares in Aetna Inc (AET) Acquired by Cpwm LLC
Cpwm LLC bought a new stake in Aetna Inc (NYSE:AET) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 1,151 shares of the company’s stock, valued at approximately $233,000.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AET. FMR LLC increased its stake in shares of Aetna by 17.2% in the 3rd quarter. FMR LLC now owns 9,063,094 shares of the company’s stock valued at $1,838,448,000 after buying an additional 1,328,607 shares during the period. PointState Capital LP grew its stake in shares of Aetna by 111.2% during the second quarter. PointState Capital LP now owns 2,193,062 shares of the company’s stock worth $402,427,000 after purchasing an additional 1,154,818 shares during the period. Diamond Hill Capital Management Inc. grew its stake in shares of Aetna by 21.3% during the third quarter. Diamond Hill Capital Management Inc. now owns 2,070,573 shares of the company’s stock worth $420,016,000 after purchasing an additional 364,121 shares during the period. Natixis grew its stake in shares of Aetna by 41.3% during the second quarter. Natixis now owns 1,235,009 shares of the company’s stock worth $226,023,000 after purchasing an additional 361,170 shares during the period. Finally, Naya Capital Management UK Ltd. acquired a new stake in shares of Aetna during the second quarter worth $61,616,000. 82.34% of the stock is owned by institutional investors.
AET stock opened at $212.70 on Friday. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.79 and a current ratio of 0.79. The stock has a market cap of $69.64 billion, a price-to-earnings ratio of 21.57, a price-to-earnings-growth ratio of 1.82 and a beta of 0.71. Aetna Inc has a 1-year low of $166.88 and a 1-year high of $213.36.
A number of equities research analysts recently commented on AET shares. Zacks Investment Research reaffirmed a “buy” rating and set a $224.00 price objective on shares of Aetna in a research note on Monday, November 12th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $204.00 price objective on shares of Aetna in a research note on Tuesday, October 30th. Citigroup lifted their price objective on Aetna from $202.00 to $206.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 31st. Credit Suisse Group decreased their price objective on Aetna from $207.00 to $205.00 and set a “neutral” rating for the company in a research note on Wednesday, October 31st. Finally, Piper Jaffray Companies cut Aetna from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $212.00 to $206.00 in a research note on Tuesday, October 30th. Six investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $207.33.
ILLEGAL ACTIVITY NOTICE: This report was reported by Watch List News and is the property of of Watch List News. If you are reading this report on another website, it was illegally stolen and republished in violation of U.S. & international copyright law. The correct version of this report can be read at https://www.watchlistnews.com/1151-shares-in-aetna-inc-aet-acquired-by-cpwm-llc/2669690.html.
Aetna Company Profile
Aetna Inc operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit management service, dental, behavioral health, and vision plans on an insured and employer-funded basis.
Recommended Story: Hedge Funds
Want to see what other hedge funds are holding AET? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aetna Inc (NYSE:AET).
Receive News & Ratings for Aetna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aetna and related companies with MarketBeat.com's FREE daily email newsletter.